CDK2 and breast carcinoma: Our ChIP assay showed that the ER did not interact with the CDK2 or CDK4 promoter region, suggesting that BC-N102 downregulated the expression of CDK2 and CDK4 independent of ER positivity in breast cancer cell lines (Figure 4E).